Formulary E-news :
Having trouble viewing this e-mail? Click here.
You are subscribed to %%list.name%% as %%emailaddr%%.
Unsubscribe from this list.
Formulary E-news
Modern Medicine Network
 
 
 
 
 
TOP SEARCHES: Dronedarone // ADHD // Tadalafil
In this issue
Antipsychotics
Alpha-blockers
Healthcare reform
CVD risk factors
Key Topic Updates

Survey

This month we would like to know...

Do you support the healthcare reform effort as it currently stands?

Vote in our survey, and see what other P&T committee members have to say.
Click here to vote

Contact Us
Click here to contact a Formulary editor.

Click here to contact a Formulary sales representative.

Click here to learn about direct mail, reprints and classifieds in Formulary.

AUGUST 19, 2009
Initiation of antipsychotic therapy associated with hyperglycemia in older diabetic patients
A case-control analysis published in the Archives of Internal Medicine demonstrated that the initiation of antipsychotic therapy in older adults with diabetes was associated with a significantly increased risk of hyperglycemia requiring hospitalization. This risk was particularly high in patients who were being treated with antipsychotics for the first time. More...
Alpha-blocker use in men associated with decreased incidence of sexual dysfunction
A study published in Urology demonstrated that alpha-blocker use is associated with a lower risk of sexual dysfunction in men aged >40 years. The study results also suggested that there was a correlation between improvement in lower urinary tract symptoms (LUTS) and decreased incidence of sexual dysfunction among patients who took alpha-blockers. More...
Healthcare reform to shape drug coverage, costs, and R&D
With healthcare-reform legislation moving forward, insurers, providers, and pharmaceutical companies are keeping a sharp eye on policy proposals likely to affect coverage, costs, and benefits. Various constituencies in the healthcare community are supporting initiatives that will increase access to healthcare and make the nation’s costly healthcare system more efficient and effective. More...
Emerging risk factors and risk markers for cardiovascular disease: Looking beyond NCEP ATP III
The current standard of care for cardiovascular disease (CVD) is to treat patients to a target low-density lipoprotein (LDL) cholesterol level, as recommended by the National Cholesterol Education Program (NCEP) Adult Treatment Panel (ATP) III. NCEP ATP III now recommends also testing some patients for emerging cardiovascular risk factors, such as levels of C-reactive protein (CRP), fibrinogen, coronary artery calcification (CAC), homocysteine, lipoprotein(a), and small, dense LDL. More...
 
Key Topic Updates
Medication Safety
Trial of sildenafil for PAH in patients with sickle cell disease terminated because of safety concerns
New warnings about malignancies in pediatric patients added to labels of TNF-blockers
Tool can significantly reduce pediatric prescription errors
Antipsychotic drugs may pose risk to older diabetics
FDA adds warning for Botox, similar products; changes generic names
Drug Pipeline/Clinical Updates
Development of bifeprunox for maintenance treatment of schizophrenia discontinued
Dirucotide trials for secondary progressive MS discontinued for lack of efficacy
Infliximab effective in arthritis resistant to methotrexate
Pulmonary hypertension may be reversible with sildenafil
Apixaban, enoxaparin show similar efficacy in trial
Regulatory/Legislative
Biologics bills duke it out in Congress
Patents set to expire soon on many brand-name drugs
HHS releases reports on health insurance reform
US health data network a powerful tool for quality
Electronic disease surveillance systems vary widely

You are subscribed to %%list.name%% as %%emailaddr%%. To unsubscribe from this list click here.To ensure delivery to your Inbox, please add %%email.list%% to your address book. If you need help doing this, click here.

Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 1-866-529-2922 at any time, or fax us at 1-218-740-6417. Outside the U.S., please phone 1-218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.